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Abstract
Background: Breast cancer is the second leading cause of cancer related deaths among females
worldwide. Berbamine (BER), a kind of bis-benzylisoquinoline alkaloid, has been used to treat
clinical patients with inflammation and cancer for many years in China. The purpose of this study is
to investigate the activity of BER against highly-metastatic human breast cancer and its molecular
mechanisms of action.
Results: In our study, we found that BER inhibits growth of highly-metastatic human breast cancer
cell lines MDA-MB-231 and MDA-MB-435S cells dose-dependently and time-dependently. The sera
from BER-treated rats suppress the growth of MDA-MB-231 cells. BER shows synergistic effects
with some existing anticancer agents such as trichostatin A (TSA, the histone deacetylase inhibitor),
celecoxib (the inhibitor of COX-2), and carmofur against the growth of MDA-MB-231 cells. BER
also displays the strong activity of inducing apoptosis in both estrogen receptor-negative MDA-MB-
231 cells and estrogen receptor-alpha-positive MCF-7 breast cancer cells, but not in normal human
mammary epithelial cell line MCF10A. BER down-regulates anti-apoptotic protein Bcl-2 levels and
up-regulates pro-apoptotic protein Bax expressions in MDA-MB-231 and MDA-MB-435S cells. BER
also has synergistic effects with anticancer agents trichostatin A, celecoxib and/or carmofur on
reducing Bcl-2/Bax ratios and VEGF secretions in MDA-MB-231 cells. In addition, BER significantly
suppresses cell migration and invasion, as well as decreases pro-MMP-9/pro-MMP-2 activation in
breast cancer cells. Furthermore, BER suppresses Akt and nuclear factor κB signaling by reducing
the phosphorylation of c-Met and Akt, and inhibiting their downstream targets such as nuclear
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factor κB p-65, Bcl-2/Bax, osteopontin, VEGF, MMP-9 and MMP-2 on protein and/or mRNA levels
in breast cancer cells.
Conclusion: Our findings have showed that BER suppresses the growth, migration and invasion
in highly-metastatic human breast cancer cells by possibly inhibiting Akt and NF-κB signaling with
their upstream target c-Met and downstream targets Bcl-2/Bax, osteopontin, VEGF, MMP-9 and
MMP-2. BER has synergistic effects with anticancer agents trichostatin A, celecoxib and carmofur
on inhibiting the growth of MDA-MB-231 cells and reducing the ratio of Bcl-2/Bax and/or VEGF
expressions in the cancer cells. These findings suggest that BER may have the wide therapeutic and/
or adjuvant therapeutic application in the treatment of human breast cancer and other cancers.
Background
Breast cancer is the second leading cause of cancer-related
deaths among females in the United States [1]. Its rate in
China and other Asian countries is also increasing rapidly
[2,3]. To find novel natural compounds with low toxicity
and high selectivity for killing cancer cells is an important
area in cancer research. To date, chemotherapy has been
the most frequently used treatment for breast cancer and
other cancers. However, some normal cells are destroyed
as well by this method of treatment. Due to their wide
range of biological activities and low toxicity in animal
models, some natural products have been used as alterna-
tive treatments for cancers including breast cancer. Ber-
bamine (BER) is a naturally occurring small-molecule
compound from Traditional Chinese Medicine (TCM)
Berberis amurensis (xiaoboan). In China, BER has been
used to treat the clinical patients with inflammation and
various cancers including breast cancer, hepatoma, leuke-
mia for many years. BER is also a clinical drug to treat the
patients with low levels of white blood cells, which are
caused by chemotherapy and/or radiotherapy. The chem-
ical structure of BER is shown in Fig. 1A. BER-induced
apoptosis and growth inhibition of human leukemia HL-
60 and K562 cell lines without cytotoxicity to normal
hematopoietic cells [4-6]. It induced caspase-3-dependent
apoptosis of leukemia NB4 cells via survivin-mediated
pathway [7]. BER also caused apoptosis and cell cycle
arrest, and led to loss of mitochondrial membrane poten-
tial and activated caspase-3 and caspase-9 in human
hepatoma cells [8]. However, whether or not BER has
inhibitory activities against highly-metastatic human
breast cancer cells is unclear. In this study, we investigated
the effects of BER on growth, migration and invasion of
highly-metastatic human breast cancer cells and its molec-
ular mechanisms of action. We showed that BER inhibited
the growth, migration and invasion of the highly-meta-
static human breast cancer cells as well as induced the
apoptosis in the cancer cells. Such anti-cancer activities of
BER involved suppression of Akt and NF-κB signaling and
its upstream and downstream targets by reducing expres-
sions of the related proteins and mRNA as well as pro-
MMP-9/pro-MMP-2 activation in the cells.
Results
In vitro and ex vivo inhibition of growth in human breast 
cancer cells by BER and its synergistic effects with 
anticancer agents in dose- and time-dependent manners
We first investigated the effects of BER on the growth of
highly-metastatic human breast cancer cell lines, MDA-
MB-231 and MDA-MB-435S. The growth of both human
breast cancer cell lines was inhibited by BER after the cells
were treated with BER at the concentrations of 1 to 80 μM
for 24, 48 and 72 h, respectively. The IC50 values at 24, 48
and 72 h were 51.6, 32.5, and 13.7 μM for MDA-MB-231
cells and (42.3 μM, 34.3 μM, and 25.0 μM) for MDA-MB-
435S cells, respectively (Fig. 1B and 1C). Furthermore, the
sera collected at 1 h and 2 h from BER-treated rats signifi-
cantly suppressed the growth of MDA-MB-231 cells after
the cells were treated with the sera for 48 and 72 h, respec-
tively, as compared with 0 h sera taken at 0 h from rats.
The 3 h sera from BER-treated rats did not show signifi-
cant inhibition of the cancer cell growth. The peak time of
the ex vivo inhibition of the cell growth by the rat sera was
between 1 h and 2 h after the rats were administered orally
with BER (Fig. 1B). In addition, BER showed the synergis-
tic effects with the existing anticancer agents celecoxib
(the inhibitor of COX-2), trichostatin A (TSA, the histone
deacetylase inhibitor), and carmofur (KA or K) against the
growth of MDA-MB-231 cells, which enhanced inhibitory
rate of the cancer cell growth more than twice. As the pos-
itive control, the anticancer agents celecoxib, trichostatin
A, carmofur, rosiglitazone, lovastatin, navelbine,
Ly294002 (the inhibitor of PI3K/Akt) and Bay (the inhib-
itor of NF-κB) showed significant inhibition of the growth
of MDA-MB-231 cells (Fig. 1D).
The strong induction of apoptosis in both estrogen-
receptor negative/highly-metastatic human breast cancer 
cells and estrogen receptor-alpha-positive human breast 
cancer cells, rather than in normal human mammary 
epithelial cells by BER
Next, we investigated effects of BER on the apoptosis of
both human breast cancer cell lines and normal human
mammary epithelial cell line. Flow cytometric analysis
further confirmed that BER at concentrations of 20 μM, 40
μM, and 60 μM displayed dose-dependent induction ofMolecular Cancer 2009, 8:81 http://www.molecular-cancer.com/content/8/1/81
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In vitro/ex vivo growth inhibition of highly-metastatic human breast cancer cell lines by berbamine (BER) Figure 1
In vitro/ex vivo growth inhibition of highly-metastatic human breast cancer cell lines by berbamine (BER). (A) 
The chemical structure of berbamine. Growth inhibition of highly-metastatic human breast cancer cell lines MDA-MB-231 (B) 
and MDA-MB-435S (C) cells after treatment for 24 hour (h), 48 h and 72 h with 1-80 μM BER (B, left panel) or the sera (B, 
right panel) taken from rats (n = 6 for each group at different time points) at 0 h (as the control group), 1 h, 2 h and 3 h after 
oral administration of BER in rats, respectively. The cell growth was determined by MTT assay. (D) In vitro effects of BER and 
its synergistic anticancer agents on growth of MDA-MB-231 cells. The cells were treated for 48 h with the indicated concentra-
tions of BER (B, 1- 40 μM), celecoxib (S, 10-80 μM), trichostatin A (T, 12.5-100 μg/L), carmofur (KA, 40 mg/L), navelbine (NA, 
5 nM), rosiglitazone (Ro1, 1 μM), lovastatin (Lo1, 1 μM), Ly294002 (LY, 12.5 and 25 μM), and Bay (5 μM) in the absence or 
presence of the synergistic anticancer agents S (20 and 40 μM), T (25 and 50 μg/L), KA (40 mg/L), LY (12.5 and 25 μM). The 
data are presented as the mean ± SD (Bar) for each group (n = 6). The figures (B, C and D) are the representative of 3 similar 
experiments performed. Comparison was made by two-way ANOVA followed by Bonferroni post hoc test to establish 
whether significant differences existed between the groups. *: P < 0.05, ***, P < 0.001. All statistical tests were two-sided. Val-
ues with different letters (a-i) differ significantly (P < 0.05). i/s, f/s and h/s represent the significant synergistic effects (P < 0.05) 
compared with the treatment with its individual compound alone. (i/s, P < 0.0001, two-way ANOVA; f/s, P < 0.001, two-way 
ANOVA; h/s, P < 0.001, two-way ANOVA).
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apoptosis in both estrogen-receptor negative and highly-
metastatic human breast cancer cell line MDA-MB-231
cells, and the estrogen receptor-alpha-positive MCF-7 cells
after the cells were treated for 48 h with BER. Whereas,
such treatment with the same concentrations of BER
(except 60 μM) did not show strong toxicity to the human
mammary epithelial cell line MCF10A (Fig. 2A and 2B).
Up-regulation of Bax protein levels and down-regulation 
of Bcl-2 protein expressions in highly-metastatic human 
breast cancer cells by BER and its synergistic effects with 
anticancer agents
Further study on the mechanisms of action of BER
induced apoptosis in the highly-metastatic human breast
cancer cells showed that the expressions of anti-apoptotic
protein Bcl-2 were down-regulated and the levels of pro-
apoptotic protein Bax were up-regulated in both MDA-
MB-231 and MDA-MB-435S cells after the cells were
treated for 48 hours with BER at concentrations of 40 μM
and 60 μM (Fig. 3A and 3B). In addition, BER displayed
the synergistic effects with anticancer agents celecoxib and
trichostatin A on reducing Bcl-2 protein expression and
increasing Bax protein level, which twice reduced the ratio
of Bcl-2 and Bax levels in MDA-MB-231 cells (Fig. 3C).
Suppression of migration and invasion as well as reduction 
of pro-matrix MMP-9/MMP-2 activation in highly-
metastatic human breast cancer cells by BER
Cancer cell migration and invasion play very important
roles in cancer metastasis. So, we further studied the
effects of BER on migration and invasion as well as the
related pro-MMP-9/pro-MMP-2 activation in MDA-MB-
231 cells. Migration assay by fibronectin-coated transwell
chamber showed that BER at low concentrations of 10 μM
and 20 μM significantly suppressed the migration of
MDA-MB-231 cells with the inhibition rate of 43.8% and
59.2%, respectively after the cells were treated for 6 h with
BER (Fig. 4A). Invasion assay in Matrigel-coated transwell
chamber indicated that BER at low concentrations of 10
μM and 20 μM significantly suppressed the invasion of
MDA-MB-231 cells with the inhibition rate of 40.0% and
54.5%, respectively after the cells were treated for 16 h
with BER (Fig. 4B). The gelatin zymography analysis fur-
ther demonstrated that the activation of pro-matrix MMP-
9 and pro-matrix MMP-2 in the supernatants of invading
MDA-MB-231 cells was suppressed markedly by BER at 1
μM, 10 μM and 20 μM (Fig. 4C).
Suppression of phosphorylation of Akt and c-Met, 
expressions of NF-κB and secretions of osteopontin and 
VEGF proteins as well as mRNA levels of MMP-2 and 
MMP-9 in highly-metastatic human breast cancer cells by 
BER
Phosphoinositide 3-kinase (PI3K)/Akt and NF-κB signal-
ing pathways are associated with the growth, migration,
invasion, angiogenesis and metastasis in cancer progres-
sion [9-18]. PI3K plays a central role in a diverse range of
cellular responses including cell growth and survival
[19,20]. Akt (also named protein kinase B) is a down-
stream signal of PI3K and a 60 KD serine/threonine kinase
and is also a critical mediator of survival signals to protect
cells from apoptosis [21,22]. Activation of the PI3K/Akt
pathway in response to cytokines leads to phosphoryla-
tion and activation of the nuclear factor NF-κB p65/RelA
subunit, which regulates expression of anti-apoptotic
genes [23,24]. Activation of NF-κB blocks the apoptotic
response in a variety of cells, including breast cancer [25].
To further clarify the mechanisms of action of BER sup-
pressing the growth and reducing the cell migration and
invasion in MDA-MB-231 cells, we investigated the effects
of BER on p-Akt, NF-κB, and their upstream target c-Met
and downstream targets OPN, VEGF, MMP-9 and MMP-2
in MDA-MB-231 cells. Western blot analysis confirmed
that BER at the concentrations of 1-60 μM significantly
suppressed the phosphorylation (Ser473) of Akt (Fig. 5A)
and NF-κB p-65 expressions (Fig. 5B) in MDA-MB-231
cells. In addition, BER at the concentrations of 5-60 μM
displayed significant reduction of the phosphorylation of
c-Met in MDA-MB-231 cells (Fig. 5C). Furthermore, ELISA
analysis indicated that BER at concentrations of 40 μM
and 60 μM markedly reduced the secretions of osteopon-
tin (OPN), a metastasis-associated protein in both MDA-
MB-231 and MDA-MB-435S (Fig. 6A) cells after the cells
were treated for 16 h with BER. There have been studies
showing that MDA-MB-231 cells can secrete VEGF
[26,27]. The present study indicated that BER at concen-
trations of 10-40 μM dose-dependently decreased the
VEGF secretion in MDA-MB-231 cells. More importantly,
BER displayed the synergistic effects with anticancer
agents trichostatin A and carmofur on reducing the secre-
tions of VEGF in MDA-MB-231 cells. Furthermore, the
anticancer agents celecoxib, rosiglitazone, lovastatin,
Ly294002 and Bay showed the reduction of the VEGF
secretions in the breast cancer cells (Fig. 6B). RT-PCR
detection demonstrated that BER at 40 μM and 60 μM dra-
matically reduced the mRNA levels of MMP-2 (Fig. 7A)
and MMP-9 (Fig. 7B) in MDA-MB-231 cells after the cells
were treated for 16 h with BER.
Discussion
Abnormal growth and metastasis of cancer cells are
regarded as the important biological characteristics of can-
cers. The presence of metastasis is the main cause of mor-
bidity and mortality in millions of patients with cancer.
During the complicated process of metastasis, the inva-
sion of cancer cells is the most important and characteris-
tic step. Clearly, an agent that could efficiently inhibit the
growth, migration and invasion of cancer cells would be a
hopeful candidate to suppress cancer progression and
metastasis and thus it could reduce mortality. In theMolecular Cancer 2009, 8:81 http://www.molecular-cancer.com/content/8/1/81
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The strong induction of apoptosis in both estrogen-receptor negative and estrogen receptor-alpha-positive breast cancer cells Figure 2
The strong induction of apoptosis in both estrogen-receptor negative and estrogen receptor-alpha-positive 
breast cancer cells. FACS analysis (A) of the cell cycles and apoptosis in estrogen-receptor negative cell line MDA-MB-231 
and estrogen receptor-alpha-positive breast cancer cell line MCF-7 as well as normal human mammary epithelial cell line MCF-
10A after the cells were treated for 48 h with BER at the indicated concentrations. The percent apoptosis(cells in subG1 phase) 
in the cells treated by BER are summarized in (B).
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Effects of BER with its synergistic anticancer agents on Bcl-2/Bax protein expressions in MDA-MB-231 cells Figure 3
Effects of BER with its synergistic anticancer agents on Bcl-2/Bax protein expressions in MDA-MB-231 cells. 
Western blot analysis of Bcl-2 (A) and Bax (B) expressions in whole-cell lysates of MDA-MB-231 (left panel) and MDA-MB-
435S (right panel) cells treated for 48 h with BER at the indicated concentrations; (C) Reduction of Bcl-2/Bax ratio in MDA-
MB-231 cells by BER and its synergistic anticancer agents celecoxib and trichostatin A. The cells were treated for 48 h with the 
indicated concentrations of BER (B, 20 μM), celecoxib (S, 20 μM), trichostatin A (T, 50 μg/L), Ly 294002 (LY, 25 μM), and Bay 
(5 μM) in the absence or presence of its synergistic anticancer agents S (20 μM) and T (50 μg/L). The expressions of Bcl-2 and 
Bax in MDA-MB-231 were analyzed by Western blotting. In the (A) and (B), the density of the band (normalized to β-actin) 
shown as mean ± SD (Bar) is relative to that of 0 as the control (designated as 100%). In the (C), the ratio of Bcl-2 and Bax, 
(the ratio of relative density of each band normalized to β-actin), shown as mean ± SD (Bar) is relative to that of 0 (0.1% 
DMSO vehicle) as the control (designated as 1.0). For one experiment, 3 assays were carried out and only one set of gels is 
shown. Comparison was made by two-way ANOVA followed by Bonferroni post hoc test to establish whether significant dif-
ferences existed between the groups. *: P < 0.05, **, P < 0.01. Values with different letters (a-e) differ significantly (P < 0.05). e/
s+ represents the significant synergistic effects (P < 0.05) compared with the treatment with its individual compound alone. Sta-
tistically significant synergistic effect on the Bcl-2/Bax ratio was observed in MDA-MB-231 cells treated with B20+S20 or 
B20+T50 compared with the individual B20, S20 or T50 treatment alone (B20+S20, P < 0.001, two-way ANOVA; B20+T50, P 
< 0.001, two-way ANOVA).
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present study, we have demonstrated that BER suppressed
the growth of highly-metastatic human breast cancer cell
lines, MDA-MB-231 and MDA-MB-435S cells in dose- and
time-dependent manners (Fig. 1B &1C). In addition, the
sera taken at 1 h and 2 h from BER-treated rats displayed
significant inhibitory effects against the growth of MDA-
MB-231 cells ex vivo although 3 h sera did not show the
significant inhibition (Fig. 1B). Whereas, we did not
observe a significant effect on the cell growth when the
cells were treated with the sera taken at 0 h, 1 h, 2 h, and
3 h from rats treated with water containing 0.9% NaCl
(data not shown). There have been reports showing that
the blood concentration of BER can be detected in rats
and BER appeared in blood of rats 5 minutes after intrave-
nous injection of BER [28]; BER appeared in blood and
lung tissue of mice about 0.1-0.25 h after oral administra-
tion of BER [29]. These results suggest that BER has a cer-
tain bioavailability by oral administration and the BER
and BER-induced changes of some factors in the sera may
produce the effects on MDA-MB-231 cells growth. More
importantly, BER showed the synergistic effects with anti-
cancer agents celecoxib, trichostatin A, and carmofur
against the growth of MDA-MB-231 cells, which
enhanced the inhibitory rate of the cancer cell growth
more than twice (Fig. 1D). These results further suggest
that BER may have therapeutic and/or adjuvant therapeu-
tic effects against the growth of human metastatic breast
cancer cells. To understand the mechanisms of action of
BER against the growth of the metastatic human breast
cancer cells, we investigated the effects of BER on induc-
tion of apoptosis in the cancer and normal human mam-
mary epithelial cells. The results indicated that BER
strongly induced the apoptosis in both estrogen-receptor
negative MDA-MB-231 cells, and estrogen receptor-alpha-
positive MCF-7 breast cancer cells, but not in normal
human mammary epithelial cell line MCF-10A (Fig. 2A
and 2B). BER reduced the Bcl-2 protein expressions (Fig.
3A) and enhanced the Bax protein expressions (Fig. 3B) in
the human breast cancer cells. Furthermore, BER dis-
played the synergistic effects with anticancer agents
celecoxib and trichostatin A on reducing Bcl-2 protein
expressions and increasing Bax protein levels, which twice
reduced the ratio of Bcl-2 and Bax levels in MDA-MB-231
cells (Fig. 3C). These data suggest that induction of apop-
tosis of MDA-MB-231 cells is possibly one of important
mechanisms of action of BER with celecoxib and trichos-
tatin A against the growth of the human breast cancer
cells.
Bcl-2 and its dominant inhibitor Bax are key regulators of
cell growth and apoptosis. Overexpression of Bcl-2
enhances cell survival by suppressing apoptosis, but over-
expression of Bax accelerates cell death. NF-κB is a nuclear
transcription regulator with a specific motif for Bcl-2 tran-
scription [30-32]. The PI3K/Akt pathway acts as a survival
(anti-apoptotic) signal and plays a key role in the regula-
tion of apoptotic change in breast cancer cells. Akt can
exert its anti-apoptotic effects in several different ways,
such as negatively regulating pro-apoptotic factors, stimu-
lating the NF-κB survival pathway [23,24,33,34]. Activa-
tion of p-Akt and the NF-κB/Bcl-2 pathway leads to
inhibition of chemotherapy-induced apoptosis, which
results in treatment resistance [25]. The Bax, Bcl-2, p-Akt
and NF-κB have become the important targets of action by
anticancer agents [25,32,35-38]. Here, we have demon-
strated that BER targets these factors in the human breast
cancer cells. We have confirmed that BER inhibits the p-
Akt and the NF-κB/Bcl-2 pathway by suppressing the
phosphorylation of Akt and NF-κB expression in MDA-
MB-231 cells (Fig. 5). This inhibition may contribute to
the down-regulation of the levels of Bcl-2 protein and up-
regulation of the levels of Bax protein in the human breast
cancer cells. Such effects may be the important mecha-
nisms of action of BER induced apoptosis and suppressed
the growth of the breast cancer cells.
Increased OPN and VEGF levels, activation of p-c-Met and
p-Akt, and enhanced expressions of NF-κB and MMP-9/
MMP-2 are associated with cancer cell growth, invasion,
and metastasis as well as angiogenesis [9-18]. The receptor
tyrosine kinase, c-Met and its ligand hepatocyte growth
factor/scatter factor (HGF/SF), have become leading can-
didates for targeted cancer therapies. Inappropriate c-Met
signaling through autocrine, paracrine, amplification, and
mutational activation occurs in virtually all types of solid
tumors, contributing to one or a combination of prolifer-
ative, invasive, survival, or angiogenic cancer phenotypes.
c-Met and HGF/SF participate in all stages of malignant
progression and represent promising drug targets in a vari-
ety of cancer types, including breast cancer [39]. The
metastasis-associated protein, OPN, was reported to stim-
ulate the motility and invasion of MDA-MB-231 cells
through PI3K/Akt and NF-κB signaling pathways [14].
VEGF is a key regulator of angiogenesis and VEGF expres-
sion correlates with tumor progression [40]. OPN and
VEGF transcriptions were inhibited by abrogating NF-κB
activation [13,16]. OPN regulated pro-MMP-9 activation
in cancer cells [15]. MMP-9 is a NF-κB-regulated gene and
is associated with invasion and metastasis, which is con-
sidered to be a therapeutic target of high priority [9,10].
MMP-2 was reported to play a direct role in OPN-induced
cancer cell migration and invasion; OPN-stimulated
MMP-2 activation occurred through NF-κB mediation
[12]. Therefore, the suppression of phosphorylation of c-
Met and the blockage of PI3K/Akt and NF-κB signaling
pathways by the anticancer compounds could possibly
inhibit the related downstream targets such as OPN,
VEGF, MMP-9 and MMP-2, and thus suppress the cancer
progression. Our present results have demonstrated that
BER suppresses the phosphorylation of c-Met and Akt asMolecular Cancer 2009, 8:81 http://www.molecular-cancer.com/content/8/1/81
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Suppression of migration and invasion and pro-matrix MMP-9/MMP-2 activation in MDA-MB-231 cells by BER Figure 4
Suppression of migration and invasion and pro-matrix MMP-9/MMP-2 activation in MDA-MB-231 cells by BER. 
MDA-MB-231 cell migration (A) was examined in the presence of BER at the indicated concentrations for 6 h in upper cham-
ber of the fibronectin-coated transwell chamber (serum-free). The right panels show the propidium iodide-stained MDA-MB-
231 cells migrating through fibronectin-coated transwell chamber. The cells were treated 6 h with the 0 (A1: vehicle as the 
control) and 20 μM BER (A2). In the (B), MDA-MB-231 cell invasion was examined in the presence of BER at the indicated con-
centrations for 16 h in upper chamber of the Matrigel-coated transwell chamber (serum-free). The right panels show the pro-
pidium iodide-stained MDA-MB-231 cells invading through Matrigel-coated transwell chamber. The cells were treated 16 h 
with the 0 (B1: vehicle as the control) and 20 μM BER (B2). Relative migration (%) ± SD (Bar) and relative invasion (%) ± SD 
are shown for the indicated BER concentrations and the 0 (vehicle) is the control. (C) Inhibition of pro-matrix MMP-9/MMP-2 
activation in supernatants of invading MDA-MB-231 cells by BER. MDA-MB-231 cells were cultured for 16 h in upper chamber 
of the Matrigel-coated transwell chamber (serum-free) in the presence of BER at 0, 1 μM, 10 μM, and 20 μM, respectively. The 
activation (Mr 72,000 and Mr 92,000 gelatinase activities) of MMP-9/MMP-2 zymogens (z-MMP-9/z-MMP-2) in the supernatants 
of invading MDA-MB-231 cells mentioned in (B) was determined by gelatin zymography analysis. Values (the relative activation 
of MMP-9/MMP-2 zymogens) are shown as mean ± SD of 3 runs (n = 3) for each sample, only one set of gels is shown. The fig-
ures (A, B and C) are the representative of 3 similar experiments performed. Statistical analysis was done using the ANOVA 
and Bonferroni test. *: P < 0.05, **, P < 0.01 (n = 6).
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well as NF-κB p65 expression (Fig. 5A, B and 5C). We have
also confirmed that BER inhibits the secretions of OPN
and VEGF proteins (Fig. 6A and 6B) and MMP-9/MMP-2
mRNA (Fig. 7A and 7B) as well as activation of pro-matrix
MMP-9/MMP-2 (Fig. 4C) in MDA-MB-231 cells. All these
suppressions by BER are possibly involved in the reduc-
tion of the migration and invasion of MDA-MB-231 cells
(Fig. 4A and 4B).
It should be noted that the breast cancer cell line MDA-
MB-435S (parental cell line MDA-MB-435) used to be
controversial a while ago but this cell line was employed
in the present study. Ross et al., and G Ellison et al. sug-
gested that MDA-MB-435 is a melanoma cell line [41,42].
However, from recent updating research, MDA-MB-435S
is indeed a breast cancer cell line. The most convincing
research is from the study by Sellappan S et al. [43]. They
have demonstrated that the MDA-MB-435 is a breast can-
cer cell line since it expressed breast-specific milk compo-
nents, including milk proteins and milk lipids, similar to
that seen in MCF-7 breast cancer cells [43]. Also two very
recent studies have firmly confirmed that MDA-MB-435 is
a breast cancer cell line [44,45]. Many influential journals
have also acknowledged that MDA-MB-435 is a breast cell
line. For example, very recently, Kalaany and Sabatini
have published their paper in Nature using MDA-MB-435
as a breast cancer cell line [46]. For these reasons men-
tioned above, we also applied MDA-MB-435S as a breast
cancer cell line along with other breast cancer cell lines
MDA-MB-231 and MCF-7 in the present study.
Conclusion
By studying the activity of BER against human breast can-
cer cells and dissecting the molecular mechanisms of
action of BER, we have demonstrated that BER signifi-
cantly suppresses the in vitro and ex vivo growth of highly
metastatic human breast cancer cells and enhances anti-
cancer activity of anticancer agents celecoxib, trichostatin
A and carmofur against the growth of MDA-MB-231 cells;
BER also displays the strong activity of inducing apoptosis
in both estrogen receptor-negative MDA-MB-231 cells and
estrogen receptor-alpha-positive MCF-7 breast cancer
cells. Down-regulation of Bcl-2 protein levels and up-reg-
ulation of pro-apoptotic Bax protein expression are possi-
bly the one of important mechanisms of action of BER
induced apoptosis in the cancer cell. BER also reduces the
migration and invasion of MDA-MB-231 cells. In addi-
tion, we have confirmed that BER suppresses the Akt and
NF-κB signaling and their upstream target c-Met and
downstream targets such as Bcl-2/Bax, OPN, VEGF, MMP-
9 and MMP-2 in protein and/or mRNA levels in MDA-
MB-231 cells, which are possibly associated with the sup-
pression of growth, migration and invasion of MDA-MB-
231 cells. Furthermore, BER shows synergistic effects with
anticancer agents celecoxib, trichostatin A and carmofur
on inhibiting the growth of MDA-MB-231 cells and reduc-
ing the ratio of Bcl-2/Bax and/or VEGF expressions in the
cancer cells. All these findings suggest that BER may have
the wide therapeutic and/or adjuvant application in the
treatment of human breast cancer and other cancers.
Methods
Reagents
Berbamine (BER, molecular weight of 681.65, Fig 1A;
purity greater than 99%) was purchased from Keji Phar-
maceutical Co. (Liaoning, China) and dissolved in double
distilled water (ddH2O) as a stock solution of berbamine.
The series of working dilutions were made in DMEM cell
culture medium. Matrigel and Boyden chambers were
purchased from BD Inc. (Franklin Lakes, NJ) and Costar,
Corning, Inc., (Corning, NY), respectively. Enhanced
chemiluminescence Western blotting detection reagents
were purchased from Amersham Pharmacia Biotech (Pis-
cataway, NJ). Antibodies against Bcl-2, Bax, NF-κB (p-65),
Akt, p-Akt, c-Met, p-c-Met and β-Actin were purchased
from Cell Signaling Technology, Inc. (Beverley, MA). Acr-
ylamide and the protein assay kit were obtained from Bio-
Rad (Hercules, CA). BER, trichostatin A (TSA or T),
Ly294002 (LY), Bay 11-7082 (Bay), propidium iodide
(PI), DMEM, penicillin, streptomycin, and 3- [4,5-
Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT), trypsin/EDTA, fetal bovine serum, gelatin and all
other chemicals employed in this study were purchased
from Sigma Chemical Co. (St. Louis, MO). Celecoxib (S),
carmofur (KA), navelbine (NA), rosiglitazone (Ro), and
lovastatin (Lo) were obtained from Yuhuangding Hospi-
tal of Yantai, Yantai, Shandong Province, China.
Animal experimentation and preparation of sera from 
BER-treated rats
SD rats (4 weeks old) were purchased from Luye Pharma-
ceutical Company, Yantai, Shandong, China. Animals
were treated in accordance with guidelines established by
the Animal Care and Use Committee at Yantai University.
The animals were kept in animal facilities for at least one
week before use, given water and a stock pellet diet (from
the Luye Pharmaceutical Company) ad libitum, and kept
in an air-conditioned room with an 8:00 a.m. to 8:00 p.m.
light cycle. The preparation of sera from BER-treated rats
was based on the methods of Zhang, et al. with slight
modifications as described previously [47,48]. In brief,
the rats were deprived of their diet at 6:00 p.m. but
allowed free access to water until oral administration of
BER which was conducted at 10:00 a.m. next day. BER was
orally intubated to the rats at a dose of 10 mg/ml/100 g
body weight. Blood samples were then collected at 0, 1, 2,
and 3 h thereafter. The collected blood was left to clot for
2 h at room temperature and centrifuged twice at 3000× g
at 4°C for 20 minutes. The sera were sterilized by filtra-
tion and then heated at 56°C for 30 minutes. The pre-Molecular Cancer 2009, 8:81 http://www.molecular-cancer.com/content/8/1/81
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Suppression of phosphorylation of Akt and c-Met as well as NF-κB expression in MDA-MB-231 cells by BER Figure 5
Suppression of phosphorylation of Akt and c-Met as well as NF-κB expression in MDA-MB-231 cells by BER. 
The cells were treated with BER at the indicated concentration and the 0 (vehicle) is the control. Equal amounts of protein 
from total cell lysates were separated by SDS-PAGE, and Western blot analysis of p-Akt (A), p-c-Met (C) and NF-κB (B) were 
done. For the analysis of phosphorylation of Akt and c-Met, the density of the band (normalized to Akt and c-Met, respectively) 
shown as mean ± SD is relative to that of 0 (vehicle) as the control (designated as 100%). For analysis of the NF-κB p65 
expression, the density of the band (normalized to β-actin) shown as mean ± SD is relative to that of 0 (vehicle) as the control 
(designated as 100%). Bay and LY (LY294.002) are the inhibitors of NF-κB and PI3K/Akt, respectively. For one experiment, 3 
assays were carried out and only one set of gels is shown. The phosphorylation of Akt and c-Met as well as NF-κB p65 expres-
sion in MDA-MB-231 cells were significantly suppressed by BER. Statistical analysis was carried out using the ANOVA and Bon-
ferroni test. *: P < 0.05 (n = 3). Values with different letters (a-c) differ significantly (P < 0.05).
CMolecular Cancer 2009, 8:81 http://www.molecular-cancer.com/content/8/1/81
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pared sera were aliquoted, and stored at -80°C until ex
vivo growth assay.
Cell culture and in vitro and ex vivo growth assays
The highly-metastatic and estrogen receptor-negative
human breast cancer cell lines MDA-MB-231 and MDA-
MB-435S, and estrogen receptor-alpha-positive human
breast cancer cell line MCF-7, and normal human mam-
mary epithelial cell line MCF-10A were obtained from the
American Type Culture Collection. MCF-7 cells were
maintained in MEM supplemented with 0.1 mM nones-
sential amino acids, 1 mM sodium pyruvate, 1.5 g/L
sodium bicarbonate, 10% fetal bovine serum, and antibi-
otics. The normal human mammary epithelial cell line
MCF-10A was cultured in serum-free mammary epithelial
growth medium (Clonetics, San Diego, CA) supple-
mented with 100 ng/mL cholera toxin (Calbiochem, La
Jolla, CA). MDA-MB-231 and MDA-MB-435S were cul-
tured in DMEM medium (Sigma, USA) containing 10%
heat-inactivated fetal bovine serum, glutamine (2 mM),
penicillin (100 U/ml) and streptomycin (100 μg/ml) at
37°C in a humidified incubator with 95% air/5% CO2
atmosphere. The in vitro and ex vivo assays were based on
the methods of Zhang, et al. with slight modifications as
described previously [47,48]. In brief, cells were cultured
in the medium mentioned above supplemented with
10% FBS (in the case of in vitro assay) containing 0-80 μM
BER alone or in combination with each anti-cancer agents
(celecoxib, trichostatin A, carmofur, navelbine, rosiglita-
zone, lovastatin, Ly294002 and Bay 11-7082), or 10% rat
sera (in the case of ex vivo assay) obtained at different time
points after BER was orally intubated to rats. Cell growth
was measured 24 h, 48 h (in the case of detection of the
synergistic effects of BER and its anticancer agents), and
72 h after the treatments using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-tetrazolium bromide (MTT) growth
assay kit (Invitrogen) following the manufacturer's
instruction. Each experiment was repeated three times.
Flow cytometry for cell cycle analysis and apoptosis
The treatment of cells was based on the methods of
Zhang, et al. as described previously [47]. MDA-MB-231,
MDA-MB-435S, MCF-7 and MCF10A were treated for 48
h with BER at concentrations of 0, 20, 40, and 60 μM. The
treated cells were detached in PBS/2 mM EDTA, centri-
fuged at 1,000 rpm for 5 min, and then gently resus-
pended in 250 μL of hypotonic fluorochrome solution
(PBS, 50 μg propidium iodide, 0.1% sodium citrate, and
0.1% Triton X-100) with RNase A (100 unite/ml). The
DNA content was analyzed by flow cytometry (Becton
Dickinson FACS Vantage SE, San Jose, CA). Twenty-thou-
sand events were analyzed per sample and the cell cycle
distribution and apoptosis were determined based on
DNA content and the sub-G1 cell population, respectively.
In vitro migration and invasion assays
Tumor cell migration and invasion were measured by
examining cell migration and invasion through fibronec-
tin- and Matrigel-coated polycarbonate filters, respec-
tively, using modified transwell chambers (Costar,
Corning, Inc., Corning, NY). In brief, MDA-MB-231 cells
(5 × 104) were seeded onto the upper chamber in 200 μL
of serum-free medium containing BER at the concentra-
tions of 0, 1 μM, 10 μM, and 20 μM, respectively; the
lower compartment was filled with 0.66 mL of DMEM
media supplemented with 10% of FBS (as a chemo-
attractant. After incubation for 6 h (in the case of migra-
tion assay) and 16 h (in the case of invasion assay) at
37°C, the cells that migrated or invaded to the lower sur-
face of the filter were fixed and stained using propidium
iodide. The cells on the upper side of the filter were
removed using a cotton swab. The migrated or invaded
cells on the underside of the filter were counted and
recorded for images under a fluorescent microscope
(Nikon, TE2000-U, Japan). Experiments were performed
in triplicate.
Gelatin zymography
The supernatants from the upper chamber of the transwell
chamber in the aformentioned serum-free invasion assay
were analyzed for pro-matrix metalloproteinase-9 (pro-
MMP-9 or z-MMP-9) and pro-matrix metalloproteinase-2
(pro-MMP-2 or z-MMP-2) activation. The conditioned
media were subjected to 10% SDS-PAGE containing 0.1%
gelatin (under non-reducing conditions). Following elec-
trophoresis, the gels were washed with 2.5% Triton X-100
to remove SDS and then incubated in a developing buffer
[50 mM Tris-HCl buffer (pH 7.4), 10 mM CaCl2] over-
night at 37°C. Gels were stained with 0.25% Coomassie
Brilliant Blue R-250 and de-stained in the same solution
without dye. Gelatinase activation was visualized as clear
bands against the blue-stained gelatin background. Each
experiment was repeated three times. The gelatin and all
other chemicals were purchased from Sigma Chemical
Co. (St. Louis, MO).
Western blot analysis
This was performed according to our previous method
[49]. In brief, MDA-MB-231 and MDA-MB-435S cells
were treated with BER at the concentrations of 0 (0.1%
DMSO vehicle as control), 40 μM, and 60 μM, and col-
lected at 48 hours. For detection of effects of BER and its
synergistic anticancer agents on Bcl-2 and Bax expressions
in MDA-MB-231 cells, the cells were treated for 48 h with
the indicated concentrations of BER (B, 20 μM), celecoxib
(S, 20 μM), trichostatin A (T, 50 μg/L), Ly 294002 (LY, 25
μM), and Bay (5 μM) in the absence or presence of its syn-
ergistic anticancer agents S (20 μM), T (50 μg/L) and Ly
(25 μM). For detection of p-Akt, the cells were treated forMolecular Cancer 2009, 8:81 http://www.molecular-cancer.com/content/8/1/81
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30 minutes with BER at different concentrations. The
treated cells were washed with ice-cold PBS and sus-
pended in lysis buffer [20 mM Tris-Cl (pH 7.4), 100 mM
NaCl, 1% NP40, 0.5% sodium deoxycholate, 5 mM
MgCl2, 0.1 mM phenylmethylsulfonyl fluoride, 0.1 mM
pepstatin A, 0.1 mM antipain, 0.1 mM chymostatin, 0.2
mM leupeptin, 10 μg/mL aprotinin, 0.5 mg/mL soybean
trypsin inhibitor, and 1 mM benzamidine] on ice for 30
minutes. Lysates were cleared by centrifugation at 13000
rpm for 20 minutes. Equal amounts of cell extracts (60 μg)
were resolved by SDS-PAGE, transferred to nitrocellulose
membranes, and probed with primary antibodies to
human Bcl-2, Bax, Nuclear factor (NF-κB p-65), Akt, p-
Akt, c-Met, p-c-Met and β-Actin and then horseradish-con-
Reduction of secretions of osteopontin (OPN) and VEGF in MDA-MB-231 cells by BER Figure 6
Reduction of secretions of osteopontin (OPN) and VEGF in MDA-MB-231 cells by BER. (A) Reduction of OPN 
secretions in MDA-MB-231 (left) and MDA-MB-435S (right) cells by BER treatment. The cells were treated for 16 h with BER 
at the indicated concentration. The secreted OPN in the cell supernatants was analyzed by ELISA described in "Materials and 
Methods" section. (B) Reduction of VEGF secretions in MDA-MB-231 cells by BER and its synergistic anticancer agents carmo-
fur (K) and trichostatin A (T). The 0 (0.1% DMSO vehicle) is the control. The cells were treated for 48 h with the indicated 
concentrations of BER (B, 10 μM, 20 μM, and 40 μM), celecoxib (S, 10 μM, 20 μM, 40 μM and 80 μM), trichostatin A (T, 25 μg/
L and 50 μg/L), carmofur (K, 40 mg/L), rosiglitazone (Ro1, 1 μM), lovastatin (Lo1, 1 μM), Ly294002 (LY, 25 μM), and Bay (5 
μM) in the absence or presence of its synergistic anticancer agents K (40 mg/L) and T (25 μg/L and 50 μg/L). The secreted 
VEGF in the supernatants of MDA-MB-231 cells was analyzed by ELISA described in "Materials and Methods" section. Values 
are shown as mean ± SD (bar) for the indicated concentration (n = 3). Comparison was made by two-way ANOVA followed 
by Bonferroni post hoc test to establish whether significant differences existed between the groups. *: P < 0.05, **, P < 0.01. 
Values with different letters (a-f) differ significantly (P < 0.05). e/s represents the significant synergistic effects (P < 0.001) com-
pared with the treatment with its individual compound alone. Statistically significant synergistic effects on the VEGF secretions 
were observed in MDA-MB-231 cells treated with B20+K40+T25, B10+K40+T50, B20+K40+T50 compared with the individ-
ual B10, B20, T25, T50, and/or K40 treatment alone (e/s, P < 0.001, two-way ANOVA).
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jugated secondary antibodies, respectively. Anti-β-Actin
antibody was used as a loading control. Detection was
done using an enhanced chemiluminescence system (GE
Healthcare Life Sciences).
ELISAs for detection of human osteopontin and VEGF 
levels in human breast cancer cells
MDA-MB-231 and MDA-MB-435S cells were treated with
BER at the concentrations of 0 (0.1% DMSO vehicle as
control), 40 μM, and 60 μM for 16 h. For detection of
effects of BER and its synergistic anticancer agents on the
secretions of vascular endothelial growth factor (VEGF) in
MDA-MB-231 cells, the cells were treated for 48 h with the
indicated concentrations of BER (B, 10 μM, 20 μM and 40
μM), celecoxib (S, 10 μM, 20 μM, 40 μM, and 80 μM), tri-
chostatin A (T, 25 μg/L, and 50 μg/L), carmofur (K, 40
mg/L), rosiglitazone (Ro1, 1 μM), lovastatin (Lo1, 1 μM),
Ly294002 (LY, 25 μM), and Bay (5 μM) in the absence or
presence of its synergistic anticancer agents K (40 mg/L)
and T (25 μg/L and 50 μg/L). Then each supernatant of the
cell culture was respectively collected and analyzed by
ELISA using kits (osteopontin and VEGF) from R & D Sys-
tems, Minneapolis, MN. ELISAs were done according to
the instructions of the manufacturer. Each experiment was
repeated three times.
Semi-quantitative reverse transcription-PCR
Total cellular RNA was extracted using TRIzol reagent
(Invitrogen, USA) from MDA-MB-231 cells treated with
BER at different concentrations (0/0.1% DMSO vehicle as
control, 40 μM, and 60 μM) for 16 h according to the
manufacturer's instructions, and quantified by spectro-
photometry. RT reaction was done using total RNA as a
template and a RT-for-PCR kit (Promega, Madison, WI).
PCR amplification was carried out with the following
primers:
MMP-2, 5'-GGATGATGCCTTTGCTCG-3' and 5'- CAGT-
GGACATGGCGGTCT-3'; MMP-9, 5'-TCCCTGGAGACCT-
GAGAACC-3' and 5'-GGCAAGTCTTCCGAGTAGTTT-3';
β-Actin, 5'-ATCATGTTTGAGACCTTCAACACC-3' and 5'-
TAGCTCTTCTCCAGGGAGG-3'.
PCR conditions included an initial denaturation of 3 min-
utes at 94°C followed by 30 cycles of denaturation for 45
seconds at 94°C, annealing for 1 minute at 60°C, and
extension for 1 minute at 72°C. Aliquots (10 μL) of the
amplification products were separated by electrophoresis
through a 1.5% agarose gel and visualized by ethidium
bromide staining. The intensity of each band was quanti-
fied using Scion Image software (Scion, Frederick, MD).
Effects of BER on mRNA expressions of MMP-2 and MMP-9 in MDA-MB-231 cells Figure 7
Effects of BER on mRNA expressions of MMP-2 and MMP-9 in MDA-MB-231 cells. The mRNA expressions were 
determined by semi-quantitative RT-PCR after the cells were treated for 16 h with BER at 0 (control), 40 μM and 60 μM. 
mRNA expression level was normalized to β-actin. For one experiment, 3 assays were carried out and only one set of gels is 
shown. The density of the band (normalized to β-actin) shown as mean ± SD is relative to that of the control (designated as 
1.00). Statistical analysis was done using the ANOVA and Bonferroni test. Significant decreases in the mRNA expressions were 
observed in MMP-2 (n = 3) and MMP-9 (n = 3). **, P < 0.01, significant difference.Molecular Cancer 2009, 8:81 http://www.molecular-cancer.com/content/8/1/81
Page 14 of 15
(page number not for citation purposes)
Results for each detected band intensity were normalized
to β-Actin band intensity values. RNA only samples that
gave completely negative results in PCR without reverse
transcriptase were used to rule out the presence of
genomic DNA contamination.
Statistical analysis
The data were expressed as mean ± standard deviation
(S.D.) and analyzed by the SPSS 13.0 software to evaluate
the statistical difference. One-way or two-way ANOVA fol-
lowed by the appropriate post hoc test (Bonferroni) was
used to establish whether significant differences existed
among groups. For confirming the synergistic effect
between BER and each individual compound, compari-
son was made by two-way ANOVA followed by Bonfer-
roni post hoc test. Values between different treatment
groups at different times were compared. Mean concentra-
tions and inhibition (%) are shown for each group; Aster-
isk P < 0.05, double asterisk P < 0.01, and triple asterisk P
< 0.001. For all tests, P values less than 0.05 were consid-
ered statistically significant. All statistical tests were two-
sided.
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